Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.
2.

Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.

Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP.

Prostate. 2004 Sep 15;61(1):12-25.

PMID:
15287090
[PubMed - indexed for MEDLINE]
3.

Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.

Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K, Murai M.

Clin Cancer Res. 2002 Dec;8(12):3885-92.

PMID:
12473604
[PubMed - indexed for MEDLINE]
Free Article
4.

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Rivière I, Larson SM, Koutcher JA, Sadelain M.

Cancer Res. 2005 Oct 1;65(19):9080-8.

PMID:
16204083
[PubMed - indexed for MEDLINE]
Free Article
5.

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M.

Nat Biotechnol. 2002 Jan;20(1):70-5.

PMID:
11753365
[PubMed - indexed for MEDLINE]
6.

Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.

Ma Q, Gomes EM, Lo AS, Junghans RP.

Prostate. 2014 Feb;74(3):286-96. doi: 10.1002/pros.22749.

PMID:
24174378
[PubMed - indexed for MEDLINE]
7.

Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.

Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY.

Clin Cancer Res. 2003 Aug 15;9(9):3260-71.

PMID:
12960111
[PubMed - indexed for MEDLINE]
Free Article
8.

DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.

Vittes GE, Harden EL, Ottensmeier CH, Rice J, Stevenson FK.

Eur J Immunol. 2011 Aug;41(8):2447-56. doi: 10.1002/eji.201141518. Epub 2011 Jul 4.

PMID:
21604260
[PubMed - indexed for MEDLINE]
9.

Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.

Lu J, Celis E.

Cancer Res. 2002 Oct 15;62(20):5807-12.

PMID:
12384542
[PubMed - indexed for MEDLINE]
Free Article
10.

Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.

Hillerdal V, Ramachandran M, Leja J, Essand M.

BMC Cancer. 2014 Jan 18;14:30. doi: 10.1186/1471-2407-14-30.

PMID:
24438073
[PubMed - indexed for MEDLINE]
Free PMC Article
11.
12.

Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells.

Wang K, Gao X, Pang J, Liu X, Cai Y, Zhang Y, Zhou J, Zhan H.

Urol Oncol. 2009 Jan-Feb;27(1):26-32. doi: 10.1016/j.urolonc.2007.09.003. Epub 2008 Jan 14.

PMID:
18367124
[PubMed - indexed for MEDLINE]
13.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.

Prostate. 2003 Mar 1;54(4):249-57.

PMID:
12539223
[PubMed - indexed for MEDLINE]
14.

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.

Bühler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U.

Cancer Immunol Immunother. 2008 Jan;57(1):43-52. Epub 2007 Jun 20.

PMID:
17579857
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.

Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S.

Immunology. 2006 Mar;117(3):419-30.

PMID:
16476062
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.

Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M.

Mol Ther. 2010 Feb;18(2):413-20. doi: 10.1038/mt.2009.210. Epub 2009 Sep 22.

PMID:
19773745
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.

Dobrenkov K, Olszewska M, Likar Y, Shenker L, Gunset G, Cai S, Pillarsetty N, Hricak H, Sadelain M, Ponomarev V.

J Nucl Med. 2008 Jul;49(7):1162-70. doi: 10.2967/jnumed.107.047324. Epub 2008 Jun 13.

PMID:
18552144
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.

Huang X, Bennett M, Thorpe PE.

Prostate. 2004 Sep 15;61(1):1-11.

PMID:
15287089
[PubMed - indexed for MEDLINE]
19.

Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.

Lupold SE, Hicke BJ, Lin Y, Coffey DS.

Cancer Res. 2002 Jul 15;62(14):4029-33. Erratum in: Cancer Res. 2012 Aug 1;72(15):3887.

PMID:
12124337
[PubMed - indexed for MEDLINE]
Free Article
20.

Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.

Fortmüller K, Alt K, Gierschner D, Wolf P, Baum V, Freudenberg N, Wetterauer U, Elsässer-Beile U, Bühler P.

Prostate. 2011 May;71(6):588-96. doi: 10.1002/pros.21274. Epub 2010 Oct 13.

PMID:
20945402
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk